Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | PPARG | P37231 | 5/20 | 0.39 |
| ▸ | CTSK | P43235 | 7/20 | 0.39 |
| ▸ | CTSS | P25774 | 7/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7788178 | 0.84 | CTSK (0.55) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL7788744 | 0.84 | CTSK (0.55) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL7781128 | 0.83 | GRIK1 (0.49) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL7788166 | 0.81 | GRIK1 (0.51) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL7785602 | 0.77 | CTSK (0.46) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL16343550 | 0.77 | CTSK (0.46) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL29046818 | 0.77 | CTSS (0.56) | CTSKCTSSCTSLCTSB | |
| SCHEMBL28752529 | 0.77 | CTSS (0.56) | CTSKCTSSCTSLCTSB | |
| SCHEMBL16343552 | 0.77 | CTSK (0.46) | PPARAPPARGCTSKCTSSCTSL | |
| SCHEMBL29063337 | 0.77 | CTSS (0.56) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | PPARA 552/4885PPARG 182/4885CTSK 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.